A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the economy. Current treatment guidelines only provide partial control, leading to varying rem
| Condition(s) | Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the economy. Current treatment guidelines only provide partial control, leading to varying remission times and recurrence rates. This study aims to use molecular subtyping and immunohistochemistry to guide treatment selection for CTCL patients, aiming to prolong clinical benefit, improve treatment safety, and reduce economic burden. |
| Who can participate | Inclusion Criteria: * Signed informed consent; * Patients with CTCL who do not respond well to targeted skin therapy (topical corticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA) and advanced stage (stage IIB-IV); * Age 18-75 years; * Expected survival time greater than 3 months (follow-up for the historical control group was greater than 3 months); Exclusion Criteria: * Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment; * Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time; * Combined with other malignant tumors, still receiving anti-tumor therapy; * Has any other active disease that may increase the risk of proto |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Peking University First Hospital |
| Locations | Beijing, Beijing Municipality, China; Beijing, Beijing Municipality, China; Beijing, Beijing Municipality, China |
| Start date | 2024-05-09 |
| NCT ID | NCT06436677 |
| Official listing | https://clinicaltrials.gov/study/NCT06436677 |